<DOC>
	<DOCNO>NCT00859703</DOCNO>
	<brief_summary>Aromatase inhibitor therapy France adjuvant reference treatment postmenopausal woman early-stage breast cancer . This treatment induce bone loss high risk fracture . This study aim document effect bisphosphonate therapy prevent bone loss osteoporotic fracture postmenopausal woman aromatase inhibitor treatment breast cancer</brief_summary>
	<brief_title>Study Assess Efficacy Risedronate Preventing Bone Loss Postmenopausal Women Treated Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Etidronic Acid</mesh_term>
	<criteria>Postmenopausal woman ( one year since last menstrual period removal ovarian function surgical radiotherapic mean ) Operated invasive breast cancer ( histologically proven ) Surgical treatment complete cycle adjuvant chemotherapy ( necessary ) complete Treated aromatase inhibitor Osteopenic ( 2.5 &lt; T score &lt; 1 ) without osteoporotic fracture With write informed consent sign With social security Women present history osteoporotic fracture T score le 2.5 least one measure site Women present clinical sign metastases Having receive hormonal treatment last 3 month Having receive treatment bisphosphonates , raloxifene , tamoxifen , parathormone , strontium ranelate , tibolone , calcitonin corticosteroid 5mg/d 3 month last year Presenting know untreated hyperthyroid Presenting know hyperadrenocorticism Patients treat follow Paget 's disease bone Presenting untreated primary hyperparathyroid Presenting indication risedronate ( know hypersensibility risedronate monosodium and/or one excipients , noncorrected hypocalcemia , pregnancy breast feeding , severe renal insufficiency inferior 30 ml/min ) Patients present malabsorption syndrome glucose/galactose Person participate another clinical trial concern medicine susceptible influence bone mass</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Aromatase inhibitor treatment</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>breast cancer</keyword>
	<keyword>bisphosphonates</keyword>
</DOC>